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Abstract
Background: Progress in lung cancer is hampered by the lack of clinically useful diagnostic
markers. The goal of this study was to provide a detailed evaluation of lung cancer tumor markers
indicative of molecular abnormalities and to assess their diagnostic utility in non-small cell lung
cancer (NSCLC) patients.
Methods: Quantitative real-time RT-PCR was used to determine LunX, CK19, CEA, VEGF-C and
hnRNP A2/B1 mRNA levels in peripheral blood and pleural fluid from NSCLC patients, compared
with those from patients with other epithelial cancer (esophagus cancer and breast cancer), benign
lung disease (pneumonia and tuberculo pleurisy) and from healthy volunteers.
Results: In peripheral blood LunX mRNA was detectable in 75.0% (33/44) of patients with NSCLC,
but not in patients with other epithelial cancer (0/28), benign lung disease (0/10) or in healthy
volunteers (0/15). In contrast, all other genetic markers were detected in patients with either
NSCLC, other epithelia cancer or benign lung disease, and in healthy volunteers. The expression
level and positive rate of LunX mRNA in peripheral blood correlated with the pathologic stage of
NSCLC (P < 0.001 and P = 0.010 respectively). Furthermore, LunX mRNA was detected in 92.9%
(13/14) of malignant pleural fluid samples and was the only marker whose expression level was
significantly different between malignant and benign pleural fluid (P < 0.001). Additionally,
expression of LunX mRNA in the peripheral blood of NSCLC patients decreased shortly after
clinical treatment (P = 0.005).
Conclusion: Of several commonly used genetic markers, LunX mRNA is the most specific gene
marker for lung cancer and has potential diagnostic utility when measured in the peripheral blood
and pleural fluid of NSCLC patients.
Background
Lung cancer is one of the leading causes of cancer death
and has become an increasingly urgent worldwide health
problem. Progress in lung cancer treatment is hampered
by a lack of diagnostic markers useful in clinical practice.
Tumor markers, including carcinoembryonic antigen
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(CEA), neuron-specific enolase (NSE), squamous cell car-
cinoma (SCC) antigen, cytokeratin 19 (CK19), vascular
endothelial growth factor-C (VEGF-C), heterogeneous
ribonuclear proteins A2/B1 (hnRNP A2/B1), muc1, BJ-
TSA-9, KS1/4 and lung-specific X protein (LunX), have
been investigated for their putative diagnostic and prog-
nostic value for lung cancer [1-7]. On the basis of RT-PCR
analysis, CEA mRNA in blood cells or in lymph nodes and
CK19 mRNA in mediastinal lymph nodes have been sug-
gested as promising tools for the detection of micrometa-
static cells in patients with lung cancer [8-11]. KS1/4 was
shown to be the most sensitive marker for detecting met-
astatic NSCLC in mediastinal lymph nodes using real-
time RT-PCR [6]. Determining CEA and NSE in pleural
fluid could enhance the diagnostic yield for malignant
effusion associated with lung cancer [12]. Additionally,
accumulating evidence suggests that hnRNP B1 expres-
sion may be useful for the early diagnosis of lung cancer,
provided that expression levels can be accurately quanti-
fied [5]. LunX, a novel human lung-specific gene, has been
reported to be a superior diagnostic marker for the detec-
tion of micrometastases in lymph nodes and peripheral
blood of NSCLC patients [1,6,13]. Although lots of stud-
ies have provided suggestive results, a definitive assess-
ment of the relative value of these molecular markers for
lung cancer is lacking.
A demonstration of the diagnostic utility of these various
tumor markers requires a detailed, direct comparison
using reliable, sensitive methodologies. Quantitative real-
time RT-PCR is a development of the RT-PCR procedure,
which is simple, rapid and automated. Most importantly,
real-time RT-PCR analysis can yield accurate estimates of
gene expression levels, differentiating between baseline
levels of gene expression in normal tissue and increased
levels in cancer cells [14,15]. Molecular diagnosis using
RT-PCR technique can detect tumor marker-expressing
cells undetectable by other means in patients with local-
ized or metastatic cancer, and may offer the most effective
solution for detecting micrometastases at the molecular
level in various types of cancer patients [16].
The purpose of this study was to evaluate the known
molecular markers,LunX, CK19, CEA, VEGF-C and hnRNP
A2/B1, for their expression in lung cancer cells in periph-
eral blood and pleural fluid using real-time RT-PCR, with
the ultimate goal of establishing a more reliable molecu-
lar diagnostic method as an adjunct to clinical decision-
making.
Methods
Patients and clinical procedures
Patients with pathologically proven non-small cell lung
cancer (NSCLC) identified by routine imaging and cyto-
logic assessments were eligible for the study. The clinical
characteristics of patients (peripheral blood and pleural
fluid groups) were shown in Table 1. Patients with other
epithelial cancer, including esophagus and breast cancer,
were studied as a control. Additionally, 12 patients with
NSCLC were investigated before and after treatment
(Table 2). Patients with a history of malignancy were
excluded from the study. Informed consent was obtained
from each subject and the research was performed in com-
pliance with the principles enunciated in the Helsinki
Declaration with the approval of the Ethics Committee of
the University of Science and Technology of China.
Table 1: Clinical characteristics of patients in this study
Peripheral blood Pleural fluid
Lung cancer Esophagus cancer Breast cancer Pneumonia Healthy Lung cancer Tuberculo 
pleurisy
Age mean (min-
max)
67(36–89) 62(39–85) 51(35–82) 67(52–83) 42(25–60) 66(36–85) 64(24–85)
Sex (M/F) 31/13 5/3 0/20 8/2 8/7 9/5 12/2
Pathologic stage
I 81 3 - - - -
II 83 8 - - - -
III 14 2 5 - - 5 -
IV 14 2 4 - - 9 -
Pathologic Typing
Squ 26 Squ 6 - - - Squ 9 -
Ade 16 Ade 2 - - - Ade 5 -
LCLC 2 - - - - LCLC -
Total number 44 8 20 10 15 14 14
Pathologic stage was determined as I, II, III or IV according to the American Joint Committee On Cancer (AJCC) TNM system. Squ = squamous 
epithelial carcinoma; Ade = adenocarcinoma; LCLC = large cell lung cancer.BMC Cancer 2008, 8:156 http://www.biomedcentral.com/1471-2407/8/156
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Collection of specimens
3 ml peripheral blood (the first 2 ml peripheral blood had
been discard for detection convenience) was collected and
treated with RBC lysis buffer (RX-2-1-2, U-gene, China),
and then nucleated cells were collected for the detection
of biomarker mRNA. 10 ml pleural fluid was inspired
from indicated patients, and centrifugated at 3500 rpm
for 10 min to pellet cells.
RNA extraction and cDNA synthesis
All reagents were purchased from Invitrogen. Total cellu-
lar RNA was extracted using the TRIZOL reagent according
to the protocol provided by the manufacturer. cDNA was
generated form total RNA by reverse transcription (RT) in
a reaction containing 4 μg total RNA, 5 μM oligo dT, 0.5
mM dNTP, 8 μl 5×Buffer, 10 mM DTT, 56 units RNase
inhibitor, 400 units of M-MLV and distilled water
(ultrapure, DNase and RNase free) in a total volume of 40
μl. The RT reaction was performed at 37°C for 50 min-
utes, followed by heating at 70°C for 15 minutes. All of
the steps were performed using sterile technique in areas
designated for RNA extraction and RT-PCR.
Real-time PCR
Quantitative real-time PCR was performed using real-time
Taq-Man technology and an ABI PRISM 7000 sequence
detector (Applied Biosystems, Foster City, CA). Gene-spe-
cific primers and Taq-Man probes were shown in Table 3.
The standard reaction contained 25 μl 2×PCR buffer
(ABsolute™ QPCR Mix, AB-1140/b), 0.5 U uracil N-glyco-
sylase (UNG) Erase enzyme (Invitrogen, Cat NO.18054-
015), 5 μl cDNA template, 0.4 μM forward and reverse
primers, 0.25 μM hybridization probe in a total volume of
50 μl. The initial PCR step was at 37°C for 10 min to acti-
vate UNG erase, followed by a 15 min hold at 95°C. PCR
reactions were performed using a total of 50 cycles con-
sisting of a 15 s melt at 95°C, followed by a 1 min anneal-
ing/extension at 60°C for CK19, CEA, VEGF-C, hnRNP
Table 2: Clinical characteristics and treatments of 12 NSCLC patients
Patient Sex Age (y) Pathologic Typing Pathologic Stage Means of treatment
1 F 64 LCLC II chemo-therapy for 7 days
2 M 70 Squ III chemo-therapy for 7 days
3 M 70 Squ III chemo-therapy for 7 days
4 F 36 Squ III chemo-therapy for 7 days
5 M 75 Ad IV chemo-therapy for 7 days
6 M 62 Squ IV interventional therapy
7 M6 5 A d I I o p e r a t i o n
8 F 58 Squ IV chemo-therapy for 7 days
9 M 55 Squ III interventional therapy
10 M 58 Squ II operation
11 M 68 Ad I operation
12 M6 1 A d I I o p e r a t i o n
Peripheral blood samples from each patient were collected 1 day before and 7 days after treatment. Pathologic stage was determined as I, II, III or 
IV according to the American Joint Committee On Cancer (AJCC) TNM system. Squ = squamous epithelial carcinoma; Ade = adenocarcinoma; 
LCLC = large cell lung cancer.
Table 3: Primer pair and probe of each biomarker for real-time PCR
Gene Sequence of selected primer pair (5'-3') Probe (5'-FAM---TAMRA-3') Amplicon 
length (bp)
Ref
LunX GCCTCATTGTCTTCTACGGGCTGTT;
CTGAGGGCATTTGTCAAGCTTCCT
CAGACCATGGCCCAGTTTGGAGGCCTG 156 This work
CK19 ACTACAGCCACTACTACACGAC;
CAGAGCCTGTTCCGTCTCAAAC
TCTGGCTGCAGATGACTTCCGAACCA 149 [17]
CEA AATAACGGGACCTATGCCTGTTT;
CCCCAACCAGCACTCCAAT
CATCTGGAACTTCTCCTGGTCTCTCAGC
TG
151 This work
VEGF-C TTCATTCCATTATTAGACGTTCCCT;
GATTATTCCACATGTAATTGGTGGG
CCAGCAACACTACCA CAGTGTCAGGCA 94 [18]
hnRNP A2/B1 GACTGTGTGGTAATGAGGGATCCT;
GCTCAACTACTCTCCCATCAATTGA
CATGGCTGAGGTTGATGCTGCCAT 133 This work
β-actin TTGCCGACAGGATGCAGAA;
GCCGATCCACACGGAGTACTT
TCATTGCTCCTCCTGAGC 101 This work
Forward primer was shown as upper sequence and reverse primer was the lower sequence in the respective primer pair. The primers and probes 
for LunX (NM_130852), CEA (NM_004363), hnRNP A2/B1 (NM_031243) and β-actin (NM_001101.2) were designed using the Primer Express 
Software (Applied Biosystems). All primers were desalted when purified and the probes were HPLC purified.BMC Cancer 2008, 8:156 http://www.biomedcentral.com/1471-2407/8/156
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A2/B1 and β-actin or a 1 min annealing/extension at 56°C
for LunX. During the DNA polymerization, the Taq-Man
probe was hydrolyzed and fluorescence emitted. When
the fluorescence signal reached 10 SDs of background, the
threshold cycle (Ct) was noted. Each sample was analyzed
in triplicate for each target gene, and mRNA was quanti-
fied by the standard curve method.
Preparation of standard curves
LunX, CK19, CEA, VEGF-C, hnRNP A2/B1 and  β-actin
cDNA were generated from A549, SK-BR-3, SK-BR-3,
K562, A549 and A549 cells (American Type Culture Col-
lection, Rockville, MD), respectively, using the specific
primers in Table 3. The PCR reaction consisted of an ini-
tial denaturation step at 94°C for 3 min, followed by 35
cycles of denaturation at 94°C, annealing at 60°C for
CK19, CEA, VEGF-C, hnRNP A2/B1 and β-actin or at 56°C
for LunX, and extension at 72°C. After purification using
a gel band purification kit (Invitrogen), the amplicon was
ligated into a TA-cloning vector pCR 2.1 (Invitrogen, Gro-
ningen, The Netherlands) and then used to transform
competent E. coli (DH5α). The sequence of the insert was
verified using an ABI Prism BigDye terminator cycle
sequencing ready reaction kit (PE Biosystems, Foster City,
CA) and an ABI Prism 377 DNA sequencer. The number
of plasmid copies was determined according to the for-
mula: Copy number =
 .  Serial  dilutions
from 1 × 102 to 1 × 108 copies of plasmids per microliter
were made in TE buffer (10 mM Tris, 0.1 M EDTA, pH 8.0)
in tubes lubricated with silicon and plasmids were
detected by real-time PCR as described above. Standard
curves were determined by plotting the Ct value against an
initial copy number of standards (serially diluted plas-
mids) for LunX, CK19, CEA, VEGF-C, hnRNP A2/B1 and β-
actin mRNA. Copy numbers of each gene marker of clini-
cal samples were calculated by interpolating sample Ct
value with standard curves of Ct values generated by serial
dilution of the corresponding standard. The copy num-
bers of LunX, CK19, CEA, VEGF-C and hnRNP A2/B1were
all further normalized to the copy number of β-actin in
each sample.
Statistical analysis
SDS 1.0 software was used to analyze the results of real-
time PCR. A regression analysis was applied to standard
curves. K Independent Samples Test (Media Test) was
used to compare the gene expression levels in peripheral
blood among NSCLC patients at different pathologic
stages. Mann-Whitney U Test was used to compare the
gene expression levels in pleural fluid between NSCLC
and tuberculo pleurisy patients. Wilcoxon Signed Ranks
Test was used for the analysis of gene expression levels in
peripheral blood of NSCLC patients before and after clin-
ical treatment. In cases where the results of gene expres-
sion were negative, the data were treated as 0 for statistical
convenience.  χ2  test was used to analyze the positive
detection rate. A value of P < 0.05 (2-tailed test) was con-
sidered significant.
Results
Establishment of real-time RT-PCR procedures for the 
gene markers
The standard curves for LunX, CK19, CEA, VEGF-C, hnRNP
A2/B1 and β-actin mRNA detection were established using
specific plasmids, as described in methods. The amplifica-
tion efficiencies of the PCR reactions were 99.3% for
hnRNPA2/B1, 100% for LunX, CEA and VEGF-C, 101% for
β-actin and 103% for CK19, indicating a near-perfect dou-
bling (100%) of product with each amplification cycle.
Using established procedures, each biomarker was
detected in specific specimens and the products were vis-
ualized on ethidium bromide-stained agarose gel (Figure
1). The expression patterns were consistent with the per-
formance of each biomarker in these specimens, which
further validated the RT-PCR procedures established for
each biomarker in this study.
LunX mRNA is the most specific gene marker for NSCLC 
cells in peripheral blood
As shown in Figure 2, LunX mRNA was detectable in the
peripheral blood from only NSCLC patients; LunX mRNA
was not detectable in the peripheral blood from patients
with other epithelial cancer, patients with pneumonia, or
healthy volunteers. In contrast, CK19  mRNA could be
detectable not only in peripheral blood from NSCLC
patients but also in blood from other epithelial cancer
patients, and there was no significant difference in the
expression levels of CK19 mRNA between the two groups
(P = 0.667). As with CK19, the difference in CEA mRNA
between the two groups was not significant (P = 0.050).
VEGF-C and hnRNP A2/B1mRNA were present at high lev-
els in peripheral blood samples from NSCLC patients,
other epithelial cancer patients, pneumonia patients and
the healthy, obviously ruling out these genes as effective
gene markers for lung cancer cells in peripheral blood.
Further, for NSCLC, the positive detection rate of LunX
mRNA was 75.0% (33 of 44) in peripheral blood, which
was similar to the positive detection rate of CK19 mRNA
(84.1%, 37 of 44) (P = 0.290), but much higher than the
positive detection rate of CEA mRNA (25.0%, 11 of 44) (P
< 0.001) (Table 4). Although CK19 mRNA appeared to be
a sensitive NSCLC detector in peripheral blood, there was
no significant difference in the positive detection rate
mass g
molecule weight g mol mol
()
(/ ) . − ××
− 60 2 1 0
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between NSCLC and other epithelial cancer groups (P =
0.106). The frequency of CEA mRNA detection in periph-
eral blood was likewise not significantly different between
NSCLC and other epithelial cancer groups (P = 0.060),
providing further confirmation that CK19  and  CEA
mRNA were not specific to lung cancer cells.
Expression of LunX mRNA in peripheral blood is 
correlated with the pathologic stage of NSCLC
The correlation of LunX mRNA expression in peripheral
blood of NSCLC patients and clinical factors was further
investigated, as shown in Table 5. Gender, age and patho-
logic type were not associated with the positive detection
rate of LunX mRNA in peripheral blood (P = 0.461, 0.425
and 0.482 respectively). However, there was an associa-
tion between different pathologic stages and the LunX
mRNA positive detection rate in peripheral blood (P =
0.010), which increased with increasing clinical severity. A
similar relationship between the levels of LunX  mRNA
expression in the peripheral blood of NSCLC patients and
pathological stages was found (P < 0.001) (Figure 3).
There was no significant difference in the mRNA expres-
sion levels of the other gene markers, CK19 (P = 0.269),
CEA (P = 0.137), VEGF-C (P = 0.183) or hnRNP A2/B1 (P
= 0.370), in peripheral blood among NSCLC patients at
different pathologic stages (Figure 3).
LunX mRNA is the most specific and sensitive gene marker 
for NSCLC cells in pleural fluid
Pleural fluid can be caused by several kinds of diseases,
including malignant lung cancer and benign lung disease.
Distinguishing between malignant pleural fluid and
benign pleural fluid is an urgent clinical concern. As
shown in Figure 4 and Table 6, the detection rates of LunX
(92.9%), CK19 (100%), CEA (85.7%), VEGF-C (78.6%)
and hnRNP A2/B1 (100%) in the malignant pleural fluid
from NSCLC patients were all high. However, only LunX
mRNA was appropriately infrequent in the benign pleural
fluid from patients with tuberculo pleurisy (7.1%, 1 of
14); all remaining markers were present in the benign
pleural fluid at high frequencies (100%, 42.9%, 64.3%
and 100% for CK19, CEA, VEGF-C and hnRNP A2/B1
mRNA, respectively) (Figure 4, Table 6). There were also
no significant differences in the expression levels of CK19
(P = 0.066), CEA  (P = 0.074),VEGF-C (P = 0.054), or
hnRNP A2/B1 (P = 0.613) mRNA between malignant and
benign pleural fluid (Figure 4). Only the expression level
of LunX mRNA was significantly different between malig-
nant and benign pleural fluid (P < 0.001) (Figure 4). Thus,
LunX mRNA was the most specific biomarker with high
sensitivity (13/14, 92.9%) among these detected markers
for the differential diagnosis of NSCLC from pleural fluid.
Expression of LunX mRNA in peripheral blood decreases 
shortly following treatment of NSCLC
An important attribute of a clinically useful diagnostic
marker is the ability to promptly demonstrate the status of
lung cancer after relevant treatments. In this study, LunX,
CK19, CEA, VEGF-C and hnRNP A2/B1 mRNA in periph-
eral blood were tracked in 12 NSCLC patients before and
after treatments (Table 2). As shown in Figure 5, the
expression levels of LunX and CK19 mRNA in peripheral
blood decreased significantly in NSCLC patients after
treatment (P = 0.005 and P = 0.047, respectively). Treat-
ment did not significantly affect the expression of VEGF-C
or hnRNP A2/B1 mRNA (P = 0.875 and P = 0.875, respec-
tively) (Figure 5), which, as demonstrated above, were
detectable at high levels in peripheral blood from both
patients and healthy (Figure 2). There was also no signifi-
cant difference in the expression of CEA mRNA after treat-
ment (P = 0.109) (Figure 5). These results, taken together
with the demonstrated specificity of LunX mRNA for lung
cancer cells and the correlation of LunX mRNA levels with
NSCLC pathologic stages, indicated that LunX mRNA in
peripheral blood might be a useful diagnostic marker for
assessing the therapeutic effect on lung cancer.
Products of each gene marker by real-time RT-PCR Figure 1
Products of each gene marker by real-time RT-PCR. 
Each biomarker was detected by real-time RT-PCR in the 
indicated samples, as described in methods. Products were 
separated by electrophoresis and visualized in ethidium bro-
mide-stained agarose gels. PB = Peripheral blood; PF = Pleu-
ral fluid.BMC Cancer 2008, 8:156 http://www.biomedcentral.com/1471-2407/8/156
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LunX mRNA is the most specific gene marker for lung cancer cells in peripheral blood Figure 2
LunX mRNA is the most specific gene marker for lung cancer cells in peripheral blood. LunX, CK19, CEA, VEGF-C, 
hnRNP A2/B1 and β-actin mRNA from each peripheral blood sample were detected by real-time RT-PCR, and mRNA copy 
number was determined by reference to the standard curve, as described in methods. The copy number of each mRNA was 
further normalized as the ratio to the copy number of β-actin in all samples. For each gene marker, when the copy number was 
less than 100, it could not be detectable as a negative case. All the negative results of each indicated gene were shown as 
number undetected. The median is marked as "---" in each group. Where the frequency of negative cases is > 50%, the median 
cannot be shown.
Table 4: Number of positive cases by each biomarker in peripheral blood
Group Total number Positive Detection Rate
LunX CK19 CEA VEGF-C hnRNP A2/B1
NSCLC 44 33/44 (75.0%) 37/44 (84.1%) 11/44 (25.0%) 37/44 (84.1%) 44/44 (100%)
Other epithelial cancer 28 0/28 (0%) 19/28 (67.9%) 13/28 (46.4%) 26/28 (92.9%) 28/28 (100%)
Pneumonia 10 0/10 (0%) 0/10 (0%) 0/10 (0%) 8/10 (80.0%) 10/10 (100%)
Healthy  15 0/15 (0%) 0/15 (0%) 0/15 (0%) 10/15 (66.7%) 15/15 (100%)
P value < 0.001* < 0.001* 0.002* 0.174* -
< 0.001# 0.106# 0.060# --
/0 . 2 9 0 $ < 0.001$ --
For each gene marker, when the copy number was less than 100, it could not be detectable as a negative case using our established real-time PCR 
assay. The positive detection rate was calculated by the number of positive cases/total number. * represented the analysis among NSCLC, other 
epithelial cancer, pneumonia and healthy groups for each biomarker. # represented the analysis between NSCLC and other epithelial cancer groups 
for each biomarker. $ represented the analysis between the biomarker and LunX for NSCLC. P values were calculated using χ2 test.BMC Cancer 2008, 8:156 http://www.biomedcentral.com/1471-2407/8/156
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Discussion
The current staging evaluation for lung cancer is based on
the presence or absence of disease in lymph nodes (hilar
and mediastinal) and distant organs (principally bone,
brain, adrenal glands, and liver) [19]. Approximately 35%
of patients are diagnosed at early stage and, as such, are
candidates for curative lung resection. However, 50% of
these patients will develop metastases and die from their
disease. Furthermore, about one fourth of patients at the
earliest stage of NSCLC (pathologically confirmed stage I)
die of tumor recurrence after radical surgery, indicating
that undetected metastases are present at the time of sur-
gery and demonstrating that conventional staging tech-
niques lack the sensitivity necessary to properly
characterize patients [20,21]. Cancer cells can be released
from a primary site and spread via the bloodstream to
form a micrometastatic deposit in distant organs [1].
However, due to their extremely low concentration, these
circulating tumor cells in peripheral blood are difficult to
detect. Thus, developing sensitive and specific detection
methods for cancer cells in peripheral blood may have
important diagnostic, prognostic and therapeutic implica-
tions [22].
In this study, we have developed quantitative real-time
RT-PCR procedures to detect potentially diagnostic tumor
markers (Figure 1). The detection of metastatic cancer
cells by RT-PCR is possible because cancer cells continue
to express genetic markers specific to the tissue from
which they originate, but which are not normally
expressed in tissue compartments that frequently harbor
metastatic foci [23,24]. Using this RT-PCR approach,
which is ideal for the detection of genes expressed at low
levels [13], we have assessed the expression of the known
molecular markers,LunX, CK19, CEA, VEGF-C and hnRNP
A2/B1, in lung cancer cells in peripheral blood and pleural
fluid. Although LunX has been previously reported to be
the most sensitive marker among the five genes LunX,
muc1, KS1/4, CEA and CK19, for detecting circulating
NSCLC cells by real-time RT-PCR in a study distinguishing
patients with NSCLC from healthy volunteers, the specif-
icity of LunX for lung cancer cells has not been tested [13].
Ours is the first study to directly compare the expression
of LunX with other biomarkers in peripheral blood and
pleural fluid, not only from NSCLC patients but also from
patients with other epithelial cancer or benign lung dis-
ease and healthy volunteers. We have found that LunX
mRNA is the most specific marker for lung cancer cells in
peripheral blood (Figure 2, Table 4) and pleural fluid (Fig-
ure 4, Table 6). Compared with LunX mRNA, CK19 and
CEA mRNA were over-expressed in other epithelial can-
cers, such as breast and esophagus cancer (Figure 2, Table
4), thus limiting their specificity for detection of lung can-
cer cells in peripheral blood. Because of lack of specificity,
VEGF-C and hnRNP A2/B1mRNA were found to be simi-
larly ineffective as genetic markers for lung cancer cells in
our quantitative real-time RT-PCR assay (Figure 2, Table
4).
Further, it was demonstrated that when one lung cancer
cell (A549 cell) was added into 3 ml peripheral blood,
LunX mRNA could be detectable as a positive case in our
established method (data not shown). For NSCLC
patients, the positive detection rate of LunX  mRNA in
peripheral blood was high, almost as high as that of CK19
mRNA, and much higher than that of CEA mRNA (Table
4). Using RT-PCR, KS1/4 was previously reported to be the
most sensitive marker among CEA, CK19, KS1/4, LunX,
muc1 and PDEF for the detection of metastatic NSCLC in
mediastinal lymph nodes, and LunX was with the second
highest sensitivity distinguishing lung cancer from lung
benign disease [6]. However,KS1/4 encodes a glycopro-
tein that is expressed on epithelial cells and is also present
on epithelial cancers, thus, like CEA and CK19, KS1/4 is
not specific to lung tissue. Another novel tumor-specific
gene BJ-TSA-9 was reported to be a marker for circulating
cancer cells in lung cancer patients, but BJ-TSA-9 alone
was not sensitive enough to detect disseminated cancer
cells in peripheral blood, and a combination of BJ-TSA-9
with LunX and SCC was required [7]. BJ-TSA-9 also suffers
from the same tissue specificity problem that plagues CEA
and  CK19. In contrast, expression of the human LunX
gene is lung-specific, and mRNA could be detected at a
concentration of 10-4 μg cancer RNA in 1 μg normal
lymph node RNA [1].
Table 5: Correlation between LunX mRNA in the peripheral 
blood and clinical factor in NSCLC patients
Clinical factor Positive cases/total cases
Sex
P value 0.461
Male 22/31 (71.0%)
Female 11/13 (84.6%)
Age
P value 0.425
≤ 60 7/11 (63.6%)
> 60 26/33 (78.8%)
Pathologic Type 
P value 0.482
Squ 18/26 (69.2%)
Ade 13/16 (81.3%)
LCLC 2/2 (100%)
Pathologic Stage
P value 0.010
I3 / 8  ( 3 7 . 5 % )
II 5/8 (62.5%)
III 11/14 (78.6%)
IV 14/14 (100%)
P values were calculated using χ2 test.BMC Cancer 2008, 8:156 http://www.biomedcentral.com/1471-2407/8/156
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A malignant pleural effusion may be the initial presenta-
tion of cancer in 10–50% of patients [25]. Cytology is the
standard method for the diagnosis of malignant effusion,
but the sensitivity of cytology was not good enough [26].
Although an aggressive diagnostic technique thoracos-
copy can be used to establish the diagnosis with a higher
sensitivity (~90%), this procedure may not be available at
all facilities and/or may be too invasive for many patients
Expression level of LunX mRNA in peripheral blood is correlated with the pathologic stage of NSCLC Figure 3
Expression level of LunX mRNA in peripheral blood is correlated with the pathologic stage of NSCLC. LunX, 
CK19, CEA, VEGF-C, hnRNP A2/B1 and β-actin mRNA from each peripheral blood sample were detected by real-time RT-PCR, 
and mRNA copy number was determined by reference to the standard curve, as described in methods. The copy number of 
each mRNA was further normalized as the ratio to the copy number of β-actin. For each gene marker, when the copy number 
was less than 100, it could not be detectable as a negative case. All the negative results of each indicated gene were shown as 
number undetected. The median is marked as "---" in each group. Where the frequency of negative cases is > 50%, the median 
cannot be shown. The K Independent Samples Test (Media Test) was used to analyze gene expression levels among NSCLC 
patients at different pathologic stages. P < 0.05 (2-tailed test) was considered significant.
Table 6: Number of positive cases by each biomarker in pleural fluid
Group Total number Positive Detection Rate
LunX CK19 CEA VEGF-C hnRNP A2/B1
NSCLC 14 13/14 (92.9%) 14/14 (100%) 12/14 (85.7%) 11/14 (78.6%) 14/14 (100%)
Tuberculo pleurisy 14 1/14 (7.1%) 14/14 (100%) 6/14 (42.9%) 9/14 (64.3%) 14/14 (100%)
P value < 0.001 - 0.018 0.678 -
For each gene marker, when the copy number was less than 100, it could not be detectable as a negative case using our established real-time PCR 
assay. The positive detection rate was calculated by the number of positive cases/total number. P values were calculated using χ2 test.BMC Cancer 2008, 8:156 http://www.biomedcentral.com/1471-2407/8/156
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[27]. The evaluation of tumor markers in pleural fluid
thus represents an alternative method for establishing the
diagnosis of malignant pleural effusion. In this study,
quantitative real-time RT-PCR was performed, for the first
time, on pleural fluid. As was the case with peripheral
blood, LunX mRNA was the most specific marker in malig-
nant pleural fluid, showing a high positive detection rate
in lung cancer (13 of 14, 92.9%), compared with the other
gene markers CK19, CEA, VEGF-C and  hnRNP A2/B1
mRNA (Figure 4, Table 6). Because determining the pres-
ence of circulating cancer cells in the peripheral blood of
NSCLC patients is significant for early disease diagnosis
and clinical therapy, a test for LunX mRNA that is able to
reveal small amounts of lung cancer cells in peripheral
blood with high specificity and sensitivity would be a
great benefit in the clinical management of lung cancer.
The potential value of differential LunX mRNA expression
in pleural fluid for diagnosing malignant effusion rein-
forces this view.
Recent mass spectroscopy studies indicate that the human
LunX gene product is also expressed in normal adult nasal
lavage fluid. Further, this expression may be up-regulated
in response to certain airway irritants, such as cigarette
smoke and dimethylbenzylamine [28,29]. Nasal lavage
fluid contains a large number of proteins that altogether
comprise a potential source for detecting and characteriz-
ing biochemical alterations associated with airway dis-
eases. In the present study, nasal lavage fluid samples were
not investigated, so the element of smoking was not
addressed in comparisons between NSCLC patients, other
epithelial cancer patients, benign lung disease patients
LunX mRNA is the most specific gene marker with high sensitivity for NSCLC cells in pleural fluid Figure 4
LunX mRNA is the most specific gene marker with high sensitivity for NSCLC cells in pleural fluid. LunX, CK19, 
CEA, VEGF-C, hnRNP A2/B1 and β-actin mRNA from each pleural fluid sample were detected by real-time RT-PCR, and mRNA 
copy number was determined by reference to the standard curve, as described in methods. The copy number of each mRNA 
was further normalized as the ratio to the copy number of β-actin. For each gene marker, when the copy number was less than 
100, it could not be detectable as a negative case. All the negative results of each indicated gene were shown as number unde-
tected. The median is marked as "---" in each group. Where the frequency of negative cases is > 50%, the median cannot be 
shown. The Mann-Whitney U Test was used to compare the gene expression levels between NSCLC and tuberculo pleurisy 
groups. P < 0.05 (2-tailed test) was considered significant.BMC Cancer 2008, 8:156 http://www.biomedcentral.com/1471-2407/8/156
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and healthy volunteers. Furthermore, as shown in Figure
2 and Table 4, LunX gene was not detectable in the periph-
eral blood of healthy volunteers, whether smokers or non-
smokers. To date, the functional role of LunX protein
remains unknown; however, LunX mRNA expression is
known to be significantly enhanced in NSCLC tumors
compared with corresponding cancer-free lung tissues [1].
In our study, we found that the expression level of LunX
mRNA in peripheral blood correlated with the pathologic
stage of NSCLC (Table 5, Figure 3). The more severe the
disease was, the higher the expression level of LunX
mRNA. Thus, the expression level of LunX  mRNA in
peripheral blood might be a valuable tool for staging
NSCLC patients clinically. Furthermore, the expression of
LunX mRNA in peripheral blood was sensitive to be influ-
enced by the treatment of NSCLC patients (Figure 5), indi-
cating that LunX mRNA expression might be associated
with lung cancer progression.
Conclusion
In this study, we demonstrate that the detection of LunX
mRNA in peripheral blood and pleural fluid by quantita-
Expression of LunX mRNA in peripheral blood decreases shortly following the treatment of NSCLC Figure 5
Expression of LunX mRNA in peripheral blood decreases shortly following the treatment of NSCLC. Peripheral 
blood samples from 12 NSCLC patients were collected 1 day before and 7 days after treatment as shown in Table 2. LunX, 
CK19, CEA, VEGF-C, hnRNP A2/B1 and β-actin mRNA were detected by real-time RT-PCR, and mRNA copy number was deter-
mined by reference to the standard curve, as described in methods. "Tb" represents 1 day before treatment and "Ta" repre-
sents 7 days after treatment. The copy number of each mRNA was further normalized as the ratio to the copy number of β-
actin. For each gene marker, when the copy number was less than 100, it could not be detectable as a negative case. All the 
negative results of each indicated gene were shown as number undetected. The Wilcoxon Signed Ranks Test was used to ana-
lyze the gene expression levels before and after clinical treatment. P < 0.05 (2-tailed test) was considered significant.BMC Cancer 2008, 8:156 http://www.biomedcentral.com/1471-2407/8/156
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tive real-time RT-PCR provides a specific and sensitive
indication of the presence of lung cancer cells. To our
knowledge, LunX mRNA is the most specific NSCLC gene
marker currently identified, and has tremendous clinical
potential as an NSCLC diagnostic tool. Because LunX
mRNA levels correlate with clinical severity and change in
response to treatment protocols, this marker may prove
valuable for NSCLC patients in the clinical decision-mak-
ing process.
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